Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., April 21, 2023 -- Vaxcyte, Inc. , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial... | April 21, 2023